Bimekizumab and Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis
Eingun James Song, MD, FAAD, Co-CMO; and Philip Mease, MD, MACR, discuss how bimekizumab’s dual IL-17A and IL-17F inhibition mechanism addresses the multidomain nature of psoriatic arthritis by significantly improving patient-reported outcomes, including pain, fatigue, work productivity and quality of life, as demonstrated in the BE OPTIMAL and BE COMPLETE phase 3 clinical trials.
EP. 1: Background on PROs in Psoriatic Arthritis
September 11th 2025Panelists discuss how patient-reported outcomes (PROs) are critical in psoriatic arthritis clinical trials because the disease affects multiple domains, including skin, joints, entheses and spine, creating a complex symptom burden that significantly impacts patients’ pain, fatigue and quality of life.
Watch
EP. 2: Common Symptoms and Treatments in Psoriatic Arthritis
September 11th 2025Panelists discuss how patients with psoriatic arthritis primarily present with pain in joints and enthesial sites, along with debilitating morning stiffness and fatigue that severely impacts their ability to perform daily activities and work functions.
Watch
